Chemotherapy News and Research

Latest Chemotherapy News and Research

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

9 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

HRG protein inhibits tumor growth and metastasis: Study

Most cancer tissues are invaded by inflammatory cells that either stimulate or inhibit the growth of the tumor, depending on what immune cells are involved. Now a Swedish-Belgian research team has shown that a protein that naturally occurs in the body, HRG, inhibits tumor growth and metastasis into secondary organs by activating specific immune cells.

7 Jan 2011

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics, announced today that it has entered into a collaboration agreement with Pfizer under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration.

7 Jan 2011

New research: NFKBIA gene loss induces glioblastoma development

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

7 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

A current New England Journal of Medicine study indicates that the use of the PARP inhibitor iniparib in combination with standard chemotherapy to treat metastatic triple-negative breast cancer offers a significant increase in clinical benefit, a measure of durable response or disease stabilization, as well as an increase in progression-free survival.

6 Jan 2011

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.

6 Jan 2011

Smiths Medical introduces new implantable ports with CT identifiers

Smiths Medical, a leading global medical devices manufacturer, announced today that they have launched new implantable ports with CT identifiers for easy viewing using X-rays or CT scout scans.

5 Jan 2011

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Application for ERWINAZE(R) has been accepted for filing and awarded Priority Review status by the U.S. Food and Drug Administration.

5 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to conduct a Phase II clinical trial in the U.S. of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

New options in fertility preservation for oncology patients

Many young people who've just learned that they have cancer also are told that the therapies that may save their lives could rob them of their ability ever to have children. Infertility caused by chemotherapy and radiation affects a sizable population: Of the 1.5 million people diagnosed with cancer in 2009, nearly 10 percent were still in their reproductive years.

4 Jan 2011

Peptide in blood and tissue inhibits growth of breast tumors

Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.

4 Jan 2011

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, and Topotarget A/S announced today that the first patient has been dosed in an Investigator Initiated Trial of belinostat in combination with Tarceva® for patients with Non-Small Cell Lung Cancer (NSCLC).

30 Dec 2010